mairei (AETC) potentiates the efficacy of osimertinib in overcoming resistance by targeting the ERK1/2/SREBP-2/HMGCR pathway and modulating cholesterol biosynthesis in cancer cells [28]. This evidence concerns the gene HMGCR and cancer.